Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 20/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372103 | 0.93 | CFTR (0.64) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL3255376 | 0.93 | CFTR (0.64) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL2927265 | 0.92 | CFTR (0.64) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| Hydrochloric Acid SCHEMBL17074569 | 0.91 | CFTR (0.63) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL3042594 | 0.91 | CFTR (0.57) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL25917885 | 0.91 | CFTR (0.59) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL20628576 | 0.90 | CFTR (0.59) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL19418866 | 0.89 | CFTR (0.55) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL4173401 | 0.88 | CFTR (0.55) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL4168455 | 0.87 | CFTR (0.57) | CFTRNR1I2ADORA3CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3925607-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3424534-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3424534-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3131582-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2018-05-23 | — | — | EP | disclosed |